S&P Futures
4,156.75-5.75(-0.14%)Dow Futures
33,885.00-38.00(-0.11%)Nasdaq Futures
13,988.25-25.75(-0.18%)
AstraZeneca PLC (AZN)
50.80 -0.03 (-0.06%)
After hours: 7:52PM EDT
Chart Events
Performance Outlook
| Previous Close | 49.84 |
| Open | 50.74 |
| Bid | 50.66 x 3000 |
| Ask | 50.97 x 3100 |
| Day's Range | 50.61 - 51.28 |
| 52 Week Range | 46.48 - 64.94 |
| Volume | 13,862,764 |
| Avg. Volume | 10,647,450 |
| Market Cap | 133.931B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 41.73 |
| EPS (TTM) | 1.22 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (2.81%) |
| Ex-Dividend Date | Feb 25, 2021 |
| 1y Target Est | 63.60 |
Fair Value
Related Research
- Editor's PickYahoo Finance
Coronavirus update: J&J vaccine pause remains, Oxford studies blood clots and COVID-19 vaccines
Blood clot concerns lack context, experts say, putting pressure on federal agencies to unpause J&J vaccinations.
- MarketWatch
Mass vaccination was never expected to go perfectly — or provide 100% protection against COVID-19
Health professionals say the Johnson & Johnson and AstraZeneca sagas, reports of vaccinated people catching the virus, and other risks are built into the entire process.
- Barrons.com
Covid-19 Disease Triggers More Ultra-Rare Blood Clots Than Vaccines, Study Finds
The risk of contracting blood clots is much higher for Covid-19 patients than from vaccines, according to a study released on Thursday. The rare blood clotting known as cerebral venous thrombosis, or CVT, occurred at a rate of 39 per million Covid 19 patients, according to researchers at the University of Oxford, the same university that helped develop the AstraZeneca vaccine. Firstly, Covid-19 markedly increases the risk of CVT, adding to the list of blood clotting problems this infection causes.
